Pharmaceutical and biotech companies are increasingly recognized for their potential to offer a sense of stability amid varied economic conditions, primarily due to the consistent demand for medical treatments. Patients typically prioritize their health needs, ensuring that these companies maintain a steady revenue stream regardless of market fluctuations.
Recently, however, there has been explosive demand in a specific treatment area that has created substantial revenue opportunities. The focus is on obesity treatments, a burgeoning sector projected to approach $100 billion by the end of the decade. Currently, Eli Lilly and Novo Nordisk are dominant players in the weight loss drug market, but many biotech companies, including Viking Therapeutics, are eager to carve out their share.
Viking Therapeutics, a firm specializing in metabolic diseases, is on the cusp of potentially transformative developments. Although it has yet to commercialize a product, the company boasts two leading weight loss candidates—an injectable and an oral formulation—both of which are moving through late-stage clinical trials. Notably, the phase 3 trial for the injectable drug VK2735 is currently ongoing, with enrollment completed ahead of schedule, suggesting strong interest from patients. The oral version of the drug is set to enter phase 3 trials soon.
Viking’s weight loss candidate belongs to the GLP-1 class of drugs, which are known to interact with hormonal pathways that regulate appetite and blood sugar levels. Existing drugs in this category, like Lilly’s Zepbound and Novo’s Wegovy, have seen overwhelming demand. At one point, supply shortages were reported due to this surge in interest. Patients often find these treatments appealing because they are effective, generally well-tolerated, and convenient for use— injectables require weekly self-administration, while new oral options necessitate daily intake.
The promising demand in the obesity treatment market indicates potential for new entrants like Viking. If the company can navigate its late-stage development successfully, it may gain significant market share and experience substantial growth. For context, Lilly’s Zepbound recently reported over $4 billion in revenue for a single quarter, highlighting the potential financial opportunity for a burgeoning biotech firm like Viking.
As of now, Viking’s stock has shown a modest increase, trading around $35.51, with a market capitalization of $4.1 billion. Historically, Viking stock has reacted positively to favorable news; after announcing encouraging phase 2 trial results for VK2735 in early 2024, the stock surged by an impressive 121% in just one trading session. While such dramatic gains may not occur with every announcement, the stock could witness double-digit increases as it progresses toward commercialization.
Despite these potential gains, it is important to temper expectations. For instance, an investment of $10,000 in Viking at the end of 2023 and held until its peak growth in early 2024 would still only yield $50,000—admirable, yet short of making one a millionaire. Historically, it is rare for a single stock to achieve that milestone for an investor. Instead, accumulating a diversified portfolio of well-chosen stocks is typically the more effective strategy for significant financial growth over time.
In light of the current trajectory of Viking Therapeutics and the expanding obesity treatment market, the company’s prospects may well position it as a valuable component within a diversified portfolio aimed at substantial future returns. If Viking continues to deliver encouraging news from its obesity program, it could solidify its standing as an essential addition to a millionaire-maker strategy.
